Summary of Scenti Biosciences Conference Call Company Overview - **Company**: Scenti Biosciences - **Industry**: Biotechnology - **Focus**: Development of cell and gene therapies for incurable diseases using a synthetic biology platform called GeneCircuits [1][2] Core Technology and Product Development - **Technology**: Logic gating technology allows targeting of previously untreatable cancers, enhancing precision and control in therapy [3][4] - **Lead Program**: Santi 202, targeting relapsed/refractory Acute Myeloid Leukemia (AML) and related cancers, currently in early-stage clinical trials [4][5] - **Manufacturing**: Scalable off-the-shelf manufacturing streamlines treatment for patients [5] Clinical Data and Efficacy - **Clinical Results**: Positive data reported at AACR 2025 meeting, with five patients achieving overall response rate (ORR) and four achieving complete response [15] - **Durability**: Longest-term patient response lasted over eight months, indicating potential for outpatient use [14][15] - **Patient Population**: AML affects over 20,000 newly diagnosed patients annually, with a 60% relapse rate within 12 months [10] Mechanism of Action - **Logic Gates**: Designed to differentiate between cancerous and healthy cells, minimizing toxicity [7][8] - **Cell Engineering**: Utilizes natural killer (NK) cells genetically modified to express proteins targeting AML cells while protecting healthy cells [11][12] - **Key Proteins**: Includes activating CAR (ACAR) targeting CD33 and FLT3, and an inhibitory CAR that protects healthy cells [12][13] Clinical Trial Design - **Phase One Trial**: Multicenter, multinational study assessing two dose levels (1 billion and 1.5 billion CAR positive NK cells) [16][17] - **Dosing Schedule**: Patients receive multiple doses, with assessments for response at 28 days [18] Safety and Tolerability - **Patient Monitoring**: Recovery of healthy blood cell counts observed post-treatment, indicating maintenance of healthy bone marrow [22][23] - **Toxicity Management**: Logic gating technology aims to reduce toxicity associated with traditional therapies [7][8] Future Directions - **Expansion Plans**: Focus on increasing patient numbers and showcasing the efficacy of logic gating technology [30][31] - **Broader Applications**: Potential to apply logic gating technology to solid tumors and other cancer types [25][28] Competitive Landscape - **Differentiation**: Scenti's approach is agnostic to genetic mutations, providing a complementary mechanism to existing therapies targeting genetic mutations in AML [32] - **Comparison with CAR T**: NK cells are preferred for AML due to their rapid action and safety profile, while T cells may be more suitable for solid tumors [33][34] Conclusion - **Outlook**: Scenti Biosciences is positioned to advance its lead program Santi 202 and explore broader applications of its technology in the oncology space, with ongoing clinical trials and promising early results [27][28]

Summary of Akari Therapeutics Conference Call (May 29, 2025) Company Overview - **Company**: Akari Therapeutics (AKTX) - **Focus**: Development of antibody drug conjugates (ADCs) with novel immuno-oncology payloads aimed at improving cancer treatment outcomes [2][5] Key Points and Arguments Novel Approach to ADCs - Akari is innovating ADCs by using immuno-oncology payloads that differ from traditional cytotoxic agents, aiming to enhance efficacy and safety in cancer treatment [3][5] - The lead asset, AKTX-101, targets TROP-2, a marker on cancer cells, and is conjugated with a novel payload called pH-1 [9][10] Mechanism of Action - The pH-1 payload targets the spliceosome, leading to cancer cell death and priming the immune system to attack similar cancer cells [8][27] - This approach aims to create immunological memory, allowing the immune system to recognize and attack cancer cells upon re-exposure [34] Clinical Development and Safety - Preclinical data shows robust activity for AKTX-101 as a single agent and in combination with checkpoint inhibitors, with favorable safety profiles observed in nonhuman primate studies [10][12] - Akari is advancing its lead ADC into IND-enabling studies to prepare for Phase 1 trials [20] Market Potential and Competitive Landscape - The ADC market is experiencing significant interest, with major pharmaceutical companies investing heavily in this space, indicating a strong opportunity for Akari's differentiated approach [22][23] - Akari's unique payload distinguishes it from competitors, which primarily use microtubule inhibitors or topo-I inhibitors [24][27] Future Directions - Akari plans to explore additional targets for its pH-1 payload, including colon, lung, and prostate cancers, which represent significant unmet medical needs [12][20] - The company is open to partnerships for further development and commercialization of its ADC platform [21][36] Additional Important Content - The transition from an inflammation-focused portfolio to oncology was driven by the potential of the pH-1 platform and the strategic direction of the company [39] - Akari's leadership team includes experienced professionals from major pharmaceutical companies, enhancing its capability to execute its vision [14][15][18] Conclusion - Akari Therapeutics is positioned to leverage its innovative ADC platform to address significant challenges in cancer treatment, with a focus on enhancing patient outcomes through novel immuno-oncology strategies [36][37]